The European approach to in-transit melanoma lesions

International Journal of Hyperthermia

Volumn 24, Issue 3, 2008, Pages 227-237

  Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemotherapy; In transit; Melanoma; Perfusion; Tumor necrosis factor

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BLEOMYCIN; CANCER VACCINE; CARBON DIOXIDE; CARBOPLATIN; CHLORMETHINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; GAMMA INTERFERON; MELPHALAN; MONOCLONAL ANTIBODY; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA; VINDESINE;

ADJUVANT THERAPY; AMPUTATION; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARBON DIOXIDE LASER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOSURGERY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; ELECTROCHEMOTHERAPY; ELECTROPORATION; EXTERNAL BEAM RADIOTHERAPY; GENE THERAPY; GRAVITY; HUMAN; HYPERTHERMIC THERAPY; INCIDENCE; INDIVIDUALIZATION; INJECTION SITE ABSCESS; INJECTION SITE ULCER; LASER SURGERY; LIMB PERFUSION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENITIS; LYMPHATIC DRAINAGE; MEDICAL RESEARCH; MELANOMA; MONOTHERAPY; PATIENT CARE; PLASTIC SURGERY; PREDICTION; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SEPSIS; SKIN NECROSIS; SKIN TRANSPLANTATION; SURGICAL APPROACH; TIME; TREATMENT OUTCOME; VASCULAR SURGERY; WOUND CLOSURE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; EUROPE; HUMANS; HYPERTHERMIA, INDUCED; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; MELPHALAN; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42049106278     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730701816402     Document Type: Article

References (57)

1. de Vries, E. and Coebergh, JW (2004) Cutaneous malignant melanoma in Europe. Eur J Cancer, 40, pp. 2355-2366.
2. Pawlik, TM, Ross, MI, Thompson, JF, Eggermont, AM and Gershenwald, JE (2005) The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. Clin Oncol, 23, pp. 4588-4590.
3. Koops, H Schraffordt, Vaglini, M., Suciu, S., Kroon, BB, Thompson, JF and Gohl, J. (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol, 16, pp. 2906-2912.
4. Francken, AB, Shaw, HM, Accortt, NA, Soong, SJ, Hoekstra, HJ and Thompson, JF (2007) Detection of first relapse in cutaneous melanoma patients: Implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol, 14, pp. 1924-1933.
5. Karakousis, CP, Balch, CM, Urist, MM, Ross, MM, Smith, TJ and Bartolucci, AA (1996) Local recurrence in malignant melanoma: Long-term results of the multi-institutional randomized surgical trial. Ann Surg Oncol, 3, pp. 446-452.
6. Borgstein, PJ, Meijer, S. and van Diest, PJ (1999) Are locoregional cutaneous metastases in melanoma predictable?. Ann Surg Oncol, 6, pp. 315-321.
7. Francken, AB, Bastiaannet, E. and Hoekstra, HJ (2005) Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol, 6, pp. 608-621.
8. Yao, KA, Hsueh, EC, Essner, R., Foshag, LJ, Wanek, LA and Morton, DL (2003) Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?. Ann Surg, 238, pp. 743-747.
9. Bastiaannet, E., Oyen, WJ, Meijer, S., Hoekstra, OS, Wobbes, T. and Jager, PL (2006) Impact of [18F]fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg, 93, pp. 243-249.
10. van Leeuwen, BL, Houwerzijl, M. and Hoekstra, HJ (2000) Educational tips in the treatment of malignant ulcerating tumours of the skin. Eur J Surg Oncol, 26, pp. 506-508.
11. Karakousis, CP, Choe, KJ and Holyoke, ED (1980) Biologic behavior and treatment of intransit metastasis of melanoma. Surg Gynecol Obstet, 150, pp. 29-32.
12. Jaques, DP, Coit, DG and Brennan, MF (1989) Major amputation for advanced malignant melanoma. Surg Gynecol Obstet, 169, pp. 1-6.
13. Gibson, SC, Byrne, DS and McKay, AJ (2004) Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg, 91, pp. 893-895.
14. Tan, JK and Ho, VC (1993) Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol, 19, pp. 985-990.
15. Strobbe, LJ, Hart, AA, Rümke, P., Israels, SP, Nieweg, OE and Kroon, BB (1997) Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res, 7, pp. 507-512.
16. Byrne, CM, Thompson, JF, Johnston, H., Hersey, P., Quinn, MJ, Hughes, T Michael and McCarthy, WH (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res, 15, pp. 45-51.
17. Gaudy, C., Richard, MA, Folchetti, G., Bonerandi, JJ and Grob, JJ (2006) Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg, 10, pp. 115-121.
18. Overgaard, J., Gonzalez, D Gonzalez, Hulshof, MC, Arcangeli, G., Dahl, O. and Mella, O. (1996) Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia, 12, pp. 3-20.
19. Creech, Jr O., Krementz, ET, Ryan, RF and Winblad, JN (1958) Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg, 148, pp. 616-632.
20. Cavaliere, R., Ciocatto, EC, Giovanella, BC, Heidelberger, C., Johnson, RO and Margottini, M. (1967) Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer, 20, pp. 1351-1381.
21. Fontijne, WP, Mook, PH, Koops, H Schraffordt, Oldhoff, J. and Wildevuur, CR (1985) Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study. Cancer, 55, pp. 1455-1461.
22. Koops, H Schraffordt, Oldhoff, J., Oosterhuis, JW and Beekhuis, H. (1987) Isolated regional perfusion in malignant melanoma of the extremities. World J Surg, 11, pp. 527-533.
23. Daryanani, D., Komdeur, R., Veen, J Ter, Nijhuis, PH, Piers, DA and Hoekstra, HJ (2001) Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol, 8, pp. 566-572.
24. Guchelaar, HJ, Hoekstra, HJ, de Vries, EGE, Uges, DR, Oosterhuis, JW and Koops, H Schraffordt (1992) Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities. Br J Cancer, 65, pp. 898-902.
25. Zwaveling, JH, Maring, JK, Clarke, FL, van Ginkel, RJ, Limburg, PC, Hoekstra, HJ, Koops, H Schraffordt and Girbes, AR (1996) High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med, 24, pp. 765-770.
26. Koops, H Schraffordt (1972) Prevention of neural and muscular lesions during hyperthermic regional perfusion. Surg Gynecol Obstet, 135, pp. 528-531.
27. Wieberdink, J., Benckhuysen, C., Braat, RP, van Slooten, EA and Olthuis, GA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol, 18, pp. 905-910.
28. Baas, PC, Hoekstra, HJ, Koops, H Schraffordt, Ooosterhuis, JW and van der Weele, LTH (1989) Results of hyperthermic isolated regional perfusion of locally metastasized melanoma of the lower extremity with melphalan with or without dactinamycin using different dosage methods. Regional Cancer Treatment, 2, pp. 87-91.
29. Hoekstra, HJ, Koops, H Schraffordt, de Vries, EGE, van Weerden, TW and Oldhoff, J. (1993) Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer, 72, pp. 1224-1229.
30. Daryanani, D., de Vries, EGE, Guchelaar, HJ, van Weerden, TW and Hoekstra, HJ (2000) Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur J Surg Oncol, 26, pp. 792-797.
31. de Wilt, JH, Hagen, TL ten, de Boeck, G., van Tiel, ST, de Bruijn, EA and Eggermont, AM (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer, 82, pp. 1000-1003.
32. Franklin, HR, Koops, H Schraffordt, Oldhoff, J., Czarnetzki, BM, Macher, E. and Kroon, BB (1988) To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol, 6, pp. 701-708.
33. Ghussen, F., Kruger, I., Groth, W. and Stutzer, H. (1988) The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer, 61, pp. 654-659.
34. Hafström, L., Rudenstam, CM, Blomquist, E., Ingvar, C., Jönsson, PE and Lagerlöf, B. (1991) Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol, 9, pp. 2091-2094.
35. Klaase, JM, Kroon, BB, van Geel, AN, Eggermont, AM, Franklin, HR and Hart, AA (1994) Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery, 115, pp. 39-45.
36. Klaase, JM, Kroon, BB, van Geel, AN, Eggermont, AM, Franklin, HR and van Dongen, JA (1993) A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer, 71, pp. 2990-2994.
37. Thompson, JF, Hunt, JA, Shannon, KF and Kam, PC (1997) Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg, 132, pp. 903-907.
38. Lienard, D., Eggermont, AM, Koops, H Schraffordt, Kroon, B., Towse, G. and Hiemstra, S. (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res, 9, pp. 491-502.
39. Fraker, DL, Alexander, H. and Ross, M. (2002) A trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma. Ann Surg Oncol, 9, p. S8.
40. Noorda, EM, Vrouenraets, BC, Nieweg, OE, van Geel, BN, Eggermont, AM and Kroon, BB (2004) Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg, 139, pp. 1237-1242.
41. Grunhagen, DJ, Brunstein, F., Graveland, WJ, van Geel, AN, de Wilt, JH and Eggermont, AM (2004) One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg, 240, pp. 939-947.
42. Rossi, CR, Foletto, M., Mocellin, S., Pilati, P. and Lise, M. (2004) Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol, 11, pp. 173-177.
43. Cornett, WR, McCall, LM, Petersen, RP, Ross, MI, Briele, HA and Noyes, RD (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: ACOSOG Trial Z0020. J Clin Oncol, 24, pp. 4196-4201.
44. Lejeune, FJ and Eggermont, AM (2007) Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol, 25, pp. 1449-1450.
45. Rüegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P. and Lejeune, FJ (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med, 4, pp. 408-414.
46. van Horssen, R., Hagen, TL Ten and Eggermont, AM (2006) TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist, 11, pp. 397-408.
47. Rossi, CR, Russano, F., Mocellin, S., Chiarion-Sileni, V., Foletto, M. and Pilati, P. TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic low-dose interferon alpha 2b in patients with in-transit melanoma metastases. A pilot. Oral presentation Society of Surgical Oncology 2007
48. Feldman, AL, Alexander Jr, HR, Bartlett, DL, Fraker, DL and Libutti, SK (1999) Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol, 6, pp. 562-567.
49. Bartlett, DL, Ma, G., Alexander, HR, Libutti, SK and Fraker, DL (1997) Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer, 80, pp. 2084-2090.
50. Grünhagen, DJ, van Etten, B., Brunstein, F., Graveland, WJ, van Geel, AN, de Wilt, JH and Eggermont, AM (2005) Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol, 12, pp. 609-615.
51. Noorda, EM, Vrouenraets, BC, Nieweg, OE, van Geel, AN, Eggermont, AM and Kroon, BB (2006) Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol, 32, pp. 318-324.
52. Noorda, EM, Vrouenraets, BC, Nieweg, OE, van Geel, AN, Eggermont, AM and Kroon, BB (2002) Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol, 9, pp. 968-974.
53. Baas, PC, Koops, H Schraffordt, Hoekstra, HJ, Oosterhuis, JW and van der Weele, LTh (1988) Isolated regional perfusion in the treatment of local recurrence, satellitosis and intransit metastases of melanomas of the extremities. Reg Cancer Treat, 1, pp. 33-36.
54. Thompson, JF, Waugh, RC and Saw, RPM (1994) Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat, 7, pp. 188-192.
55. Lindner, P., Doubrovsky, A., Kam, PCA and Thompson, JF (2002) Prognostic factors after isolated limb infusion with cytostatic agents for melanoma. Ann Surg Oncol, 9, pp. 127-136.
56. Lindner, P., Thompson, JF, De Wilt, JH, Colman, M. and Kam, PC (2004) Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol, 30, pp. 433-439.
57. Sasse, AD, Sasse, EC, Clark, LG, Ulloa, L. and Clark, OA (2007) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev, 1, p. CD005413.